Will Viking Therapeutics be acquired before 2027?

Prediction markets put the probability at 20%: Will Viking Therapeutics be acquired before 2027. Currently, markets see this as unlikely (20% YES). Polymarket traders are watching one biotech more closely than any other for an acquisition.

What’s Happening

Polymarket traders currently assign a 20% probability that Viking Therapeutics will be acquired before 2027, a notable decline from the 38.5% implied probability recorded in late May and the 25.5% level seen in early April. The contract has accumulated over $1.68 million in all-time volume, making it one of the most actively traded biotech acquisition wagers on the platform. The central asset driving this speculation is VK2735, a dual GLP-1/GIP agonist in Phase III trials that represents one of the most advanced obesity candidates not yet owned by a major pharmaceutical firm. Viking's market capitalization sits near $3.3 billion, a valuation one analyst has characterized as a bargain given the consensus price target of $92.72 per share against a current trading price below $33. [24/7 Wall St., May 26]

The probability shift reflects a complex interplay of clinical milestones and structural headwinds. Wall Street maintains 17 Buy ratings and just 2 Holds on Viking, with the upcoming Phase III oral trial data for VK2735 representing the next major catalyst. However, the company's complete lack of commercial infrastructure poses a significant execution risk — building a global sales force to challenge Novo Nordisk and Eli Lilly would require steep, highly dilutive capital raises. This structural deficiency is precisely why an acquisition remains the most plausible path to value realization, yet it also explains why the market has tempered its expectations: potential acquirers may be waiting for clearer Phase III data before committing to a deal. The addition of a DACRA pipeline candidate with an IND filed in Q1 2026 adds further optionality for any prospective buyer. [Alphastreet, Feb 23]

Buyout speculation around Viking Therapeutics being acquired has re-accelerated in July, driven by the company's rapidly expanding obesity franchise and an upcoming clinical data readout that could bolster investor confidence. The GEN Top 10 Takeover Targets of 2026 list marks Viking's second consecutive year on the ranking, citing the late-stage development of VK2735 as the primary attraction. The obesity drug market remains the most contested therapeutic area in biopharma, with major players aggressively seeking to fill pipeline gaps. For Viking, the near-term focus centers on the Phase III oral trial results — a positive readout would likely increase acquisition pressure, while a miss could push the probability of a deal below current levels. The July 9 resurgence in buyout buzz suggests traders are positioning ahead of this binary event, with the 20% probability reflecting both the genuine strategic appeal of the asset and the inherent uncertainty of deal timing in a sector where negotiations often remain opaque until completion. [TradingView, Jul 09]

Traded on Polymarket — $1.7M Volume

Active market on Polymarket with $1.7M in total volume. Sufficient liquidity for most position sizes. Currently priced at 20c YES.